Anika Therapeutics (ANIK) 47.89 $ANIK Arena (AR
Post# of 273257
Posted On: 09/04/2016 5:07:51 AM
Anika Therapeutics (ANIK) 47.89 $ANIK
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), ARNA: 1.57 (+0.01)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:30AM CDT
Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Get Nice Earnings Surprise With These 5 Stocks
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:30AM CDT
Your search for tickers with the potential of positive earnings surprise ends here.
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:38AM CDT
Keryx Biopharmaceuticals (KERX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
ANIK: 47.89 (-0.05), KERX: 4.15 (+0.02)
Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)
Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:30AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) shares rose over 20% in the last trading session.
VNDA: 15.55 (+0.26), ANIK: 47.89 (-0.05)
Anika to Participate in Upcoming Investor Conferences
BusinessWire - Thu Aug 25, 3:05PM CDT
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced that its Chief Financial Officer, Sylvia Cheung, will participate in the following upcoming investor conferences:
ANIK: 47.89 (-0.05)
Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:28AM CDT
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:51AM CDT
Xenetic (XBIO) announced that the FDA has accepted the company's Investigational New Drug application to initiate a phase II study on Virexxa.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 21.03 (+0.17), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), ARNA: 1.57 (+0.01)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:30AM CDT
Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Get Nice Earnings Surprise With These 5 Stocks
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:30AM CDT
Your search for tickers with the potential of positive earnings surprise ends here.
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:38AM CDT
Keryx Biopharmaceuticals (KERX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
ANIK: 47.89 (-0.05), KERX: 4.15 (+0.02)
Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)
Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:30AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) shares rose over 20% in the last trading session.
VNDA: 15.55 (+0.26), ANIK: 47.89 (-0.05)
Anika to Participate in Upcoming Investor Conferences
BusinessWire - Thu Aug 25, 3:05PM CDT
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced that its Chief Financial Officer, Sylvia Cheung, will participate in the following upcoming investor conferences: ANIK: 47.89 (-0.05)
Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:28AM CDT
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:51AM CDT
Xenetic (XBIO) announced that the FDA has accepted the company's Investigational New Drug application to initiate a phase II study on Virexxa.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 21.03 (+0.17), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
(0)
(0)Scroll down for more posts ▼